Preview: Cytek Biosciences's Earnings

Cytek Biosciences (NASDAQ:CTKB) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-05. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Cytek Biosciences will report an earnings per share (EPS) of $0.00.

The announcement from Cytek Biosciences is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

Performance in Previous Earnings

In the previous earnings release, the company missed EPS by $0.05, leading to a 9.43% drop in the share price the following trading session.

Here's a look at Cytek Biosciences's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

-0.03

-0.04

0

0.03

EPS Actual

-0.08

-0.05

0.04

-0.05

Price Change %

-9.0%

-1.0%

-12.0%

12.0%

Stock Performance

Shares of Cytek Biosciences were trading at $5.11 as of November 01. Over the last 52-week period, shares are up 15.73%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analyst Insights on Cytek Biosciences

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Cytek Biosciences.

The consensus rating for Cytek Biosciences is Outperform, based on 1 analyst ratings. With an average one-year price target of $8.0, there's a potential 56.56% upside.

Comparing Ratings Among Industry Peers

The analysis below examines the analyst ratings and average ...